BioXcel Therapeutics Inc (BTAI) - Total Assets
Based on the latest financial reports, BioXcel Therapeutics Inc (BTAI) holds total assets worth $44.79 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of BioXcel Therapeutics Inc for net asset value and shareholders' equity analysis.
BioXcel Therapeutics Inc - Total Assets Trend (2015–2024)
This chart illustrates how BioXcel Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
BioXcel Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
BioXcel Therapeutics Inc's total assets of $44.79 Million consist of 97.5% current assets and 2.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 77.9% |
| Accounts Receivable | $131.00K | 0.3% |
| Inventory | $679.00K | 1.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how BioXcel Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BioXcel Therapeutics Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BioXcel Therapeutics Inc's current assets represent 97.5% of total assets in 2024, an increase from 50.0% in 2015.
- Cash Position: Cash and equivalents constituted 77.9% of total assets in 2024, up from 0.0% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is inventory at 1.8% of total assets.
BioXcel Therapeutics Inc Competitors by Total Assets
Key competitors of BioXcel Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910
|
Korea | ₩344.02 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs525.46 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥56.56 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
|
China | CN¥7.26 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
|
China | CN¥1.69 Billion |
|
Hainan Honz Pharmaceutical Co
SHE:300086
|
China | CN¥1.88 Billion |
BioXcel Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.17 | 1.87 | 18.33 |
| Quick Ratio | 1.16 | 1.81 | 18.33 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $6.60 Million | $22.23 Million | $205.22 Million |
BioXcel Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between BioXcel Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.97 |
| Latest Market Cap to Assets Ratio | 0.68 |
| Asset Growth Rate (YoY) | -48.0% |
| Total Assets | $38.34 Million |
| Market Capitalization | $26.24 Million USD |
Valuation Analysis
Below Book Valuation: The market values BioXcel Therapeutics Inc's assets below their book value (0.68x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: BioXcel Therapeutics Inc's assets decreased by 48.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for BioXcel Therapeutics Inc (2015–2024)
The table below shows the annual total assets of BioXcel Therapeutics Inc from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $38.34 Million | -47.98% |
| 2023-12-31 | $73.70 Million | -64.20% |
| 2022-12-31 | $205.85 Million | -14.03% |
| 2021-12-31 | $239.44 Million | +8.87% |
| 2020-12-31 | $219.94 Million | +504.35% |
| 2019-12-31 | $36.39 Million | -16.43% |
| 2018-12-31 | $43.55 Million | +3113.95% |
| 2017-12-31 | $1.35 Million | +19257.14% |
| 2016-12-31 | $7.00K | +250.00% |
| 2015-12-31 | $2.00K | -- |
About BioXcel Therapeutics Inc
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. I… Read more